Hsa_circ_0011292 regulates paclitaxel resistance partially through regulating CDCA4 expression by serving as a miR-3619-5p sponge in non-small cell lung cancer-Reference-Cited by-同舟云学术

Hsa_circ_0011292 regulates paclitaxel resistance partially through regulating CDCA4 expression by serving as a miR-3619-5p sponge in non-small cell lung cancer

Published:2022-07-22 Issue:2 Volume:19 Page:383-393
ISSN:1738-642X
Container-title:Molecular & Cellular Toxicology
language:en
Short-container-title:Mol. Cell. Toxicol.

Author:

Bao Yanan,Cui Yue,Luan Yumin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,General Pharmacology, Toxicology and Pharmaceutics,Toxicology,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13273-022-00269-3.pdf

Reference37 articles.

1. Chang A (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer (amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2010.08.022

2. Chen ZY, Liu HY, Jiang N, Yuan JM (2019) LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621. Eur Rev Med Pharmacol Sci 23:9939–9946. https://doi.org/10.26355/eurrev_201911_19560

3. Fang H, Sheng S, Chen B, Wang J, Mao D, Han Y, Liu Y, Wang X, Gui S, Zhang T, Zhang L, Li C, Hu X, Deng W, Liu X, Xu H, Xu W, Wang X, Liu R, Kong W (2022) A pan-cancer analysis of the oncogenic role of cell division cycle-associated protein 4 (CDCA4) in human tumors. Front Immunol 13:826337. https://doi.org/10.3389/fimmu.2022.826337

4. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937

5. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SYS, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005